BLOOD CANCER DOESN’T DISCRIMINATE

Together, we’re striving for equal access to care and treatments for all patients. 

Royalty Pharma plc is partnering with The Leukemia & Lymphoma Society (LLS) over the next five years with an incredible total commitment of $7.5 million to ensure a future of expanded access and better outcomes for all blood cancer patients. The largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, Royalty Pharma will help support three LLS initiatives focused on reducing disparities in blood cancer care and treatment:

Equity in Access Research Program – a program based on the concept of health equity as the principle underlying a commitment to reduce—and ultimately, eliminate—disparities in health. 

LLS IMPACT* Research Grants – established to improve access to clinical trials for underrepresented patients, including Black, Indigenous and People of Color (BIPOC) patients and people from rural communities.

Myeloma Link - an initiative to raise community awareness about myeloma, connect Black patients and caregivers to free myeloma information, and support and offer enhanced access to care and the latest treatments. 

*Royalty Pharma is a founding donor of the LLS IMPACT grant program.